OTC$SMNR

Semnur Pharmaceuticals Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Headline financials

Total Revenue

$0.00

No prior period
EPS

$0.06

Previous: $0.00+1354.5%
Capital Expenditures

$0.00

No prior period
Free Cash Flow

-$159K

No prior period
Net Income

$553K

Previous: $41.7K+1227.9%
Operating Income

-$182K

Previous: -$2.14M+91.5%
Gross Profit

$0.00

Previous: $0.00
Cash & Equivalents

$204K

No prior period
Total Assets

$50.7M

No prior period

Revenue & EPS history

Denali Capital Acquisition-A · Revenue · Quarterly

$0

Q4 2023

Historical earnings impact

How earnings announcements have historically affected this stock's price.

+0.2%

Avg return

Earnings day

Avg return

5 days after

Avg return

30 days after

63%

5 / 8 earnings

Positive

+8.5%

Q4 2023

Best reaction

-8.0%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2025
Q1 2025
Q3 2024-0.8%
Q2 2024+1.6%
Q1 2024-8.0%
Q4 2023+8.5%
Q3 2023+0.1%
Q2 2023+0.2%
Q1 2023+0.0%
Q4 2022+0.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro